Recently, indoleamine 2,3‐dioxygenase (IDO) inhibitors have also been trialled, without success, with neoadjuvant immunotherapy in untreated LA HNSCC to improve pathological response.43 This evidence concerns the gene IDO2 and head and neck squamous cell carcinoma.